Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929330 | 1.00 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL14581384 | 1.00 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15223382 | 0.91 | CASP3 (0.53) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31453048 | 0.91 | CASP3 (0.53) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29445616 | 0.89 | CASP3 (0.51) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13652772 | 0.89 | CASP3 (0.51) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL3269193 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13452269 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31068390 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL5021152 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112386707-B | Tumor targeting polypeptide drug conjugate and preparation method thereof | 辽宁医学诊疗科技研发中心有限公司 | 2023-08-11 | — | — | CN | claimed |
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | WINKEY TECH USA INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4706670-A1 | PSD-95 DOMAIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-12492225-B2 | Melanocyte-regulating peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-4650362-A1 | NEUROPROTECTIVE PSD-95 POLYPEPTIDE INHIBITOR AND USE THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250186360-A1 | LIQUID-LIQUID PHASE SEPARATION (LLPS)-BASED COMPARTMENTS COMPRISING A SHORT PEPTIDE AND AN ANIONIC POLYMER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| EP-4532513-A1 | CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2025-04-09 | — | — | EP | disclosed |
| CN-115746097-B | Antibacterial peptide AS-12W and preparation method and application thereof | 中国药科大学 | 2025-03-21 | — | — | CN | disclosed |
| US-20250092087-A1 | THIOAMIDE ANALOGUES OF PEPTIDE ANTIGENS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-03-20 | — | — | US | disclosed |
| CN-119451974-A | Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens | 巴塞罗那全球健康研究所私人基金会 | 2025-02-14 | — | — | CN | disclosed |
| CN-114573686-A | Polypeptide containing disulfide bond and having serine protease activity inhibition function and application thereof | 中国医学科学院药物研究所 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022111713-A1 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022106825-A1 | COMPOSITIONS | UNIVERSITY OF SOUTHAMPTON (GB) | 2022-05-27 | — | — | WO | disclosed |
| EP-3986439-A1 | COMPOSITIONS AND METHODS USEFUL IN TREATING BRAIN DISEASES | University of Kansas (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986914-A1 | CONSTRAINED PEPTIDES | TearSolutions, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-109678944-B | Antibacterial polypeptide HF-18 and preparation method and application thereof | 中国药科大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-106866793-B | Polypeptide compound and preparation method and application thereof | 韩苏 | 2022-04-19 | — | — | CN | disclosed |
| CN-114245800-A | Melanocyte regulatory peptides | IDP研发制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-22 | — | — | US | disclosed |
| CN-114206916-A | Restricted peptides | 缇尔索卢森公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492225-B2 | Melanocyte-regulating peptides | MC1R, MITF, MCHR1 | CASP3 4704/4885KMT2A 995/4885EPHX2 3556/4885 |
| US-20250092087-A1 | THIOAMIDE ANALOGUES OF PEPTIDE ANTIGENS | TAP1, TAP2, DNPEP | CASP3 1991/4885KMT2A 2242/4885EPHX2 3241/4885 |
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | ARGLU1, ARG1, POT1 | CASP3 2153/4885KMT2A 1602/4885EPHX2 4180/4885 |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | TP53, MDM2, MDM4 | CASP3 2615/4885KMT2A 3182/4885EPHX2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.